Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biotraces in Blood Samples Can Diagnose Early-Stage Brain Tumor

By LabMedica International staff writers
Posted on 20 Jun 2023

Diagnosing early-stage brain tumors is not only challenging, but certain issues can also arise even after symptoms begin to show. More...

Now, a new, noninvasive method for diagnosing gliomas, one of the deadliest brain tumors, has been developed by researchers. The team achieved this by using Raman spectroscopy to identify chemical compounds known as biotraces, secreted by the tumor, in the blood.

Scientists at Tomsk State University (Tomsk, Russia) initially sourced information from specialized literature about the types of biological markers found in glioma tissues. Following this, they conducted an experiment on lab mice, who were administered human glioblastoma cells. After different time periods, their blood serum was evaluated and the mice were subsequently removed from the study. The scientists utilized Raman spectroscopy to detect specific frequencies which enabled them to find glioma traces in biological fluids, thereby segregating the mice into healthy and afflicted groups. The gathered data was compiled into a library which was used to train a neural network, automating the analysis process.

The researchers believe that this novel method could potentially be beneficial for detecting different types of tumors. All malignant growths secrete unique chemical compounds. If the exact biotraces linked to a particular condition are known, they could be identified using Raman spectroscopy and machine learning. Optical analysis methods are gaining traction across numerous fields, specifically for their potential to quickly diagnose diseases. In line with this, the scientists at TSU are employing AI to develop new noninvasive methods for diagnosing viral and bacterial respiratory infections that can cut down the analysis time from several days to mere minutes.

"What makes our approach advantageous is that it enables us to find traces of an early-stage tumor, prior to symptoms manifesting themselves," said Yury Kistenev, head of the TSU Laboratory of Laser Molecular Imaging and Machine Learning. "The thing is, a glioblastoma changes the biochemical composition of blood. It secretes substances and tumor cells that end up in blood, which carries them around the whole body. By analyzing these biotraces we can get data on cancer formation: That information in turn can be used to diagnosing a disease or monitoring the effectiveness of treatment."

Related Links:
Tomsk State University 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.